Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel

已完结 10 由 lubiao 发布于 2026/9/29 15:18:43

DOI:10.1016/j.ctrv.2026.103216
作者：Francesco Mattana, Erica Palesandro, Valentino Dragonetti, Giuseppe Curigliano, Marcello Tucci, Francesco Ceci
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundThe management of metastatic castration-resistant prostate cancer (mCRPC) after progression on androgen receptor pathway inhibitors (ARPI) and docetaxel presents a critical therape

应助信息

16小时前

FLK

202609291519510422589.pdf 已采纳

16小时前

Book学术机器人

2026/9/29 15:18:43 未找到该文献，机器人已退出，请等待人工下载

2026/9/29 15:18:43 Book学术AI机器人收到请求，开始寻找文献

2026/9/29 15:18:43 已向机器人发送请求

16小时前

lubiao 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Chemical Society (ACS)Dynamic Molecular Conformational Isomerization-Driven Halide Exchange of Perovskite Enabling Ultrastable and Low-Threshold Violet-Blue Lasing